CTLA4 and metastatic melanoma: For example, it has been reported that the combination of anti-PD-1 and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody treatment results in a longer progression-free survival (PFS) than single agent therapy among previously untreated patients with metastatic melanoma [30].